Literature DB >> 29355490

Expression of ICAM-1, E-cadherin, periostin and midkine in metastases of pancreatic ductal adenocarcinomas.

Katharina Grupp1, Nathaniel Melling2, Valentina Bogoevska3, Matthias Reeh4, Faik Güntac Uzunoglu5, Alexander Tarek El Gammal6, Michael Fabian Nentwich7, Jakob Robert Izbicki8, Dean Bogoevski9.   

Abstract

Development and progression of malignant tumors is in part characterized by the ability of a tumor cell to overcome cell-cell and cell-matrix adhesion and to disseminate in organs distinct from that in which they originated. This study was undertaken to analyze the clinical significance of the expression of the following cell-cell and cell-matrix adhesion molecules in pancreatic ductal adenocarcinomas (PDACs) and synchronous liver metastases: intercellular adhesion molecule 1 (ICAM-1), E-cadherin, periostin, and midkine (MK). ICAM-1, E-cadherin, periostin and MK expression was analyzed by immunohistochemistry on a tissue microarray containing 34 PDACs and 12 liver metastasis specimens. ICAM-1 expression was predominantly localized in the membranes of the cells and was found in weak to moderate intensities in PDACs and liver metastases. E-cadherin expression was absent in the majority of PDACs and corresponding liver metastases. The secreted proteins periostin and MK were expressed in various intensities in primary cancers and liver metastases. Statistical analysis demonstrated that the expression levels of the analyzed markers were neither significantly associated with metastasis in PDACs nor with clinical outcome of patients. Our study shows that the expression of the cell-cell and cell-matrix adhesion molecules ICAM-1, E-cadherin, periostin and MK was not significantly linked to metastatic disease in PDACs. Moreover, our study excludes the analyzed markers as prognostic markers in PDACs.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  E-cadherin; ICAM-1; Liver metastasis; Midkine; Pancreatic cancer; Periostin

Mesh:

Substances:

Year:  2018        PMID: 29355490     DOI: 10.1016/j.yexmp.2018.01.005

Source DB:  PubMed          Journal:  Exp Mol Pathol        ISSN: 0014-4800            Impact factor:   3.362


  4 in total

Review 1.  Midkine (MDK) growth factor: a key player in cancer progression and a promising therapeutic target.

Authors:  Panagiota S Filippou; George S Karagiannis; Anastasia Constantinidou
Journal:  Oncogene       Date:  2019-12-04       Impact factor: 9.867

2.  Periostin and CA242 as potential diagnostic serum biomarkers complementing CA19.9 in detecting pancreatic cancer.

Authors:  Dong Dong; Li Jia; Lufang Zhang; Na Ma; Aimin Zhang; Yunli Zhou; Li Ren
Journal:  Cancer Sci       Date:  2018-07-24       Impact factor: 6.716

3.  Prognostic and Clinicopathological Significance of E-Cadherin in Pancreatic Cancer Patients: A Meta-Analysis.

Authors:  Pengbo Wang; Zengkuan Zhu
Journal:  Front Oncol       Date:  2021-04-12       Impact factor: 6.244

4.  Relationship between cachexia and perineural invasion in pancreatic adenocarcinoma.

Authors:  Livia Petrusel; Ioana Rusu; Daniel Corneliu Leucuta; Radu Seicean; Ramona Suharoschi; Paula Zamfir; Andrada Seicean
Journal:  World J Gastrointest Oncol       Date:  2019-12-15
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.